Ico Therapeutics (ICOTF) 0.0251 $ICOTF iCo Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board

Jun 5, 2016 at 4:11 PM

Ico Therapeutics (ICOTF) 0.0251 $ICOTF

iCo Therapeutics Announces First Quarter 2016 Financial Results
CNW Group - Wed May 25, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2016. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"

.
ICO.VN: 0.035 (-0.005)

iCo Therapeutics Announces Year End 2015 Financial Results
CNW Group - Thu Apr 14, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the year ended December 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"

.
ICO.VN: 0.035 (-0.005)

iCo Strategic Reorganization
CNW Group - Mon Jan 18, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today announced that effective immediately, in an effort to preserve its asset base and maximize shareholder value, the company is undertaking a strategic re-organization.
ICO.VN: 0.035 (-0.005)

iCo Therapeutics Announces Changes to Board of Directors
CNW Group - Thu Dec 24, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today announced the appointment of Susan Koppy and John Meekison to iCo's Board of Directors.
ICO.VN: 0.035 (-0.005), NVS: 80.95 (+0.24)

/C O R R E C T I O N from Source -- iCo Therapeutics Inc./
PR Newswire - Tue Nov 24, 6:21PM CST
In the news release, iCo Therapeutics Announces Third Quarter 2015 Financial Results, issued today by iCo Therapeutics Inc. over CNW, we are advised by the company that in the paragraph Summary Third Quarter 2015 Results, the last sentence should have read "Immune Pharmaceuticals Inc.", rather than "Immune Therapeutics Inc." as originally issued inadvertently. The complete, corrected release follows:
ICO.VN: 0.035 (-0.005), IMNP: 0.34 (-0.03)

iCo Therapeutics Announces Third Quarter 2015 Financial Results
CNW Group - Tue Nov 24, 4:00PM CST
iCo Therapeutics ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"

.
ICO.VN: 0.035 (-0.005)

iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
CNW Group - Mon Oct 26, 7:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) today announced that the company has engaged Corealis Pharma Inc. ("Corealis"

a contract manufacturing organization, for analytical development, formulation optimization and scale-up of the amphotericin B oral delivery system. The preparation and regulatory filings for this program are expected to be completed in 2016, with Phase 1A study data available in 2017.
ICO.VN: 0.035 (-0.005)

iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders
PR Newswire - Fri Jun 26, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today announced that all nominees listed in the management information circular dated June 1, 2015 were elected as directors at its 2015 Annual Meeting of Shareholders, held earlier today, June 26 2015. On a vote by ballot, the following 5 nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:
ICO.VN: 0.035 (-0.005)

Immune Pharmaceuticals Inc. (Nasdaq: IMNP) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri May 22, 9:00AM CDT
What:
IMNP: 0.34 (-0.03), NDAQ: 65.07 (-0.08)

Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee
PR Newswire - Tue Apr 21, 7:30AM CDT
Immune Pharmaceuticals Inc., or "Immune" (NASDAQ: IMNP) announced that its Board of Directors has elected Rene-Pierre Azria as a Director and the Chair of the Transaction and Pricing Committee, with oversight on strategic and financial transactions. Mr. Azria will also be a member of the Audit Committee, the Compensation Committee and the Corporate Governance and Nomination Committee.
ICO.VN: 0.035 (-0.005), IMNP: 0.34 (-0.03)

Immune Pharmaceuticals to Develop Novel Topical Nanoparticle Formulation of AmiKet
PR Newswire - Mon Mar 16, 3:15PM CDT
Immune Pharmaceuticals Inc. ("Immune", the "Company"

(NASDAQ: IMNP) announced today that it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents in order to facilitate the development of a topical nanoparticle formulation of Immune's neuropathic pain drug, AmiKet(TM).
ICO.VN: 0.035 (-0.005), IMNP: 0.34 (-0.03)

CEO Dr. Daniel Teper of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014
Marketwired - Tue Dec 09, 10:13AM CST
Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), a company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, announced today that CEO Daniel Teper will be interviewed live tomorrow by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's The Traders Network Show. In this exclusive 2-segment interview, Mr. Teper will discuss the company's lead product candidate, Bertilimumab, which is in clinical development for moderate to severe ulcerative colitis and crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
IMNP: 0.34 (-0.03)

iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
PR Newswire - Fri Nov 28, 4:00PM CST
iCo Therapeutics ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"

.
ICO.VN: 0.035 (-0.005)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lincoln Educational Faces Investor Lawsuit Over Revenue Drop

Investors Face Rough Waters Okay, let’s dive into this latest mess at Lincoln Educational Services Corp. (NASDAQ:LINC). Things aren't smelling too rosy over at their headquarters. If you've got shares here, you’ll know what I mean. Back in early May, the folks running Lincoln threw a garden party talking up a 19.5% growth in student starts. Who wouldn’t get behind...

Medicare Limits and Long-Term Care Planning Tips

Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...

PZZA Faces Class Action: Strategic Shake-up or Misstep?

Papa John's: Doughy Deceit or Strategic Misfire? Once in a while, a corporation trips over its own ambitious production line, and Papa John’s (NASDAQ:PZZA) is the latest contestant to make headlines for all the wrong reasons. Investors in this pizza powerhouse are being called to the courtroom as a class action lawsuit unfolds, marking a turbulent stage in the...

Amy Johnson Steps Up as GDIT President Amid Shifts

A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...

Shanghai and Hamburg Celebrate 40 Years of Collaboration

Strengthening the Bond: A Four-Decade Journey With fireworks of diplomacy and cooperation lighting up, Shanghai and Hamburg marked the 40th anniversary of their friendship with an ambition to deepen and broaden ties. These cities, separated by continents but united by their maritime spirit, decided to toast not just the past but also the future. This isn't just some fancy...

FDA Nod for Subcutaneous SKYRIZI in Crohn's Disease

AbbVie's Injection Makes Waves in Crohn's Treatment Here's a bit of medicine shake-up for you. AbbVie just snagged FDA approval for its subcutaneous SKYRIZI—specifically designed for adults battling moderately to severely active Crohn's disease. This news isn't just a blip on the radar; it's significant for patients and the healthcare landscape. We're talking about new...

Dimora Medical Boosts Advanced Wound Care at HS Conference

Empowering the HS Community with Innovations Look, if you’ve walked a mile in someone else's shoes—particularly ones dealing with hidradenitis suppurativa (HS)—you’d know what a relentless grind managing those exuding wounds can be. Dimora Medical, known for navigating the tricky territory of wound care, threw its hat into the ring at the HS Connect Empower...

Innventure Faces Chaotic Legal Storm Over DarkNX Scandal

Innventure's DarkNX Project: From Boon to Bane The stock market is no stranger to seismic shifts, but Innventure, Inc.'s recent plunge is a testament to the catastrophic impact missteps can unleash. This whole DarkNX debacle feels more like a meticulous car wreck than a business evolution. Unpacking the Allegations Sitting comfortably under the NASDAQ:INV ticker,...

Northern Virginia's Housing Inventory Surges Despite Market Pressures

Unexpected Surge in Northern Virginia's Inventory Walking around Fairfax these days, you might feel like you're in a time warp, especially if you're tracking the housing market. See, while the rest of the country's housing market groans under sluggish sales and creeping prices, Northern Virginia's doing a dance of its own. Inventory's ballooning faster than a parade...

Hexagon Composites to Release Q3 2026 Results Soon

Anticipating Hexagon's Third Quarter 2026 Results Hexagon Composites ASA, based out of Oslo, Norway, is setting the stage to release its third quarter 2026 financial results. Mark your calendars for November 6, 2026, at the early bird hour of 07:00 am CET. For those of us keen on dissecting the numbers, that's when the real action begins. Executive Insights Await A...